Xortx appoints chief financial officer

Calgary, alberta, aug. 04, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of james fairbairn as chief financial officer to replace amar keshri who left the company's employ effective july 31, 2023. james fairbairn was appointed interim chief financial officer on june 28, 2023.
XRTX Ratings Summary
XRTX Quant Ranking